Yakir Rottenberg1, Arash Naeim2, Beatrice Uziely3, Tamar Peretz3, Jeremy M Jacobs4. 1. The Department of Oncology, Hadassah-Hebrew University Medical Center, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel; The Jerusalem Institute of Aging Research, Hadassah-Hebrew University Medical Center Mount Scopus, Hebrew University-Hadassah Medical School, Mount Scopus, Jerusalem, Israel. Electronic address: ryakir@hadassah.org.il. 2. Divisions of Hematology-Oncology and Geriatric Medicine, Department of Medicine and Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, 10911 Weyburn Avenue, Los Angeles, CA 90095, United States. 3. The Department of Oncology, Hadassah-Hebrew University Medical Center, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel. 4. The Jerusalem Institute of Aging Research, Hadassah-Hebrew University Medical Center Mount Scopus, Hebrew University-Hadassah Medical School, Mount Scopus, Jerusalem, Israel; The Department of Geriatrics and Rehabilitation, Hadassah-Hebrew University Medical Center Mount Scopus, Hebrew University-Hadassah Medical School, Mount Scopus, Jerusalem, Israel. Electronic address: JacobsJ@hadassah.org.il.
Abstract
PURPOSE OF STUDY: To describe the association between increasing age and survival among women aged over 65 years, diagnosed with breast cancer. MATERIALS AND METHODS: A historical prospective cohort study, comparing 3270 breast cancer patients to 13,163 non cancer age matched controls. Baseline characteristics and cancer data gathered from the Israeli Central Bureau of Statistics (1995), the Israel Cancer Registry (2000-2010). Baseline measurements included age, socioeconomic status. Cancer stage at diagnosis was clustered as stage I, stage II-III and metastatic. Cox Proportional Hazards regression models were used to determine Hazards Ratios (HR) for mortality. RESULTS: Between ages 65-69 and ≥85, metastatic disease rose from 3.9% to 23.4% and stage I disease declined from 58.6% to 30.1%. At age 80-84, 50% life expectancy among controls, stage I, and stage II-III disease was 95,92 and 90 months respectively, compared to 2 months for metastatic disease. Compared to controls, between the age 65-69 to ≥85, adjusted HR's progressively decreased among subjects with stage I from HR 0.96 (95% CI 0.69-1.33) to 0.60 (95%CI 0.36-1.01), stage II-III from HR 3.26 (95%CI2.58-4.12) to HR 1.60 (95%CI 1.22-2.09), and metastatic disease from HR 57.40 (95%CI 39.56-83.29) to HR 20.76 (95%CI 14.73-29.24). CONCLUSIONS: This study describes the increasingly poor prognosis and short life expectancy observed among women aged ≥80 diagnosed with metastatic breast. In contrast, our findings confirm the positive prognosis associated with rising age, among older women presenting with stage I breast cancer, among whom survival was similar, if not slightly better, than non-cancer age matched controls.
PURPOSE OF STUDY: To describe the association between increasing age and survival among women aged over 65 years, diagnosed with breast cancer. MATERIALS AND METHODS: A historical prospective cohort study, comparing 3270 breast cancerpatients to 13,163 non cancer age matched controls. Baseline characteristics and cancer data gathered from the Israeli Central Bureau of Statistics (1995), the Israel Cancer Registry (2000-2010). Baseline measurements included age, socioeconomic status. Cancer stage at diagnosis was clustered as stage I, stage II-III and metastatic. Cox Proportional Hazards regression models were used to determine Hazards Ratios (HR) for mortality. RESULTS: Between ages 65-69 and ≥85, metastatic disease rose from 3.9% to 23.4% and stage I disease declined from 58.6% to 30.1%. At age 80-84, 50% life expectancy among controls, stage I, and stage II-III disease was 95,92 and 90 months respectively, compared to 2 months for metastatic disease. Compared to controls, between the age 65-69 to ≥85, adjusted HR's progressively decreased among subjects with stage I from HR 0.96 (95% CI 0.69-1.33) to 0.60 (95%CI 0.36-1.01), stage II-III from HR 3.26 (95%CI2.58-4.12) to HR 1.60 (95%CI 1.22-2.09), and metastatic disease from HR 57.40 (95%CI 39.56-83.29) to HR 20.76 (95%CI 14.73-29.24). CONCLUSIONS: This study describes the increasingly poor prognosis and short life expectancy observed among women aged ≥80 diagnosed with metastatic breast. In contrast, our findings confirm the positive prognosis associated with rising age, among older women presenting with stage I breast cancer, among whom survival was similar, if not slightly better, than non-cancer age matched controls.
Authors: Anne Cecília Nascimento da Cruz; Dalci José Brondani; Temístocles I Talo de Santana; Lucas Oliveira da Silva; Elizabeth Fernanda da Oliveira Borba; Antônio Rodolfo de Faria; Julianna Ferreira Cavalcanti de Albuquerque; Sylvie Piessard; Rafael Matos Ximenes; Blandine Baratte; Stéphane Bach; Sandrine Ruchaud; Francisco Jaime Bezerra Mendonça Junior; Marc-Antoine Bazin; Marcelo Montenegro Rabello; Marcelo Zaldini Hernandes; Pascal Marchand; Teresinha Gonçalves da Silva Journal: Pharmaceuticals (Basel) Date: 2019-11-17
Authors: Henry Ruiz-Garcia; Lina Marenco-Hillembrand; Jennifer L Peterson; Katherine Tzou; Timothy D Malouff; Kaisorn L Chaichana; Daniel M Trifiletti; Laura Vallow Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241